Obesity in the Elderly – On the Role of Adipokines in Prostate Cancer Progression
improvements in metabolic profile through expansion of adipose tissue, J Clin Invest, 2007;117:2621–37.
9. Kahn SE, Prigeon RL, Schwartz RS, et al., Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity, J Nutr, 2001;131:354S–60S.
10. Greenberg AS, Obin MS, Obesity and the role of adipose tissue in inflammation and metabolism, Am J Clin Nutr, 2006;83:461S–465S.
11. Dandona P, Aljada A, Chaudhuri A, et al., Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation, Circulation, 2005;111:1448–54.
12. Cousin B, Munoz O, Andre M, et al., A role for preadipocytes as macrophage-like cells, FASEB J, 1999;13:305–12.
13. Weisberg SP, McCann D, Desai M, et al., Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 2003;112:1796–808.
14. Trayhurn P, Wood IS, Adipokines: inflammation and the pleiotropic role of white adipose tissue, Br J Nutr, 2004;92:347–55.
15. Kerckhoffs DA, Blaak EE, Van Baak, Saris WH, Effect of aging on beta-adrenergically mediated thermogenesis in men, Am J Physiol, 1998;274:E1075–9.
16. Harris T, Cook EF, Garrison R, et al., Body mass index and mortality among nonsmoking older persons. The Framingham Heart Study, JAMA, 1988;259:1520–4.
17. Allison DB, Gallagher D, Heo M, et al., Body mass index and all-cause mortality among people age 70 and over: the Longitudinal Study of Aging, Int J Obes Relat Metab Disord, 1997;21:424–31.
18. Kragelund C, Omland T, A farewell to body-mass index?, Lancet, 2005;366:1589–91.
19. Zamboni M, Mazzali G, Zoico E, et al., Health consequences of obesity in the elderly: a review of four unresolved questions, Int J Obes (Lond), 2005;29:1011–29.
20. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health, Obes Res, 1998;6(Suppl. 2):51S–209S.
21. Cao Y, Ma J, Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis, Cancer Prev Res (Phila), 2011;4:486–501.
22. Arai Y, Takayama M, Gondo Y, et al., Adipose endocrine function, insulin-like growth factor-1 axis, and exceptional survival beyond 100 years of age, J Gerontol A Biol Sci Med Sci, 2008;63:1209–18.
23. Kirkland JL, Dobson DE, Preadipocyte function and aging: links between age-related changes in cell dynamics and altered fat tissue function, J Am Geriatr Soc, 1997;45:959–67.
24. Gregerman RI, Aging and hormone-sensitive lipolysis: reconciling the literature, J Gerontol, 1994;49:B135–9.
25. Yki-Jarvinen H, Kiviluoto T, Nikkila EA, Insulin binding and action in adipocytes in vitro in relation to insulin action in vivo in young and middle-aged subjects, Acta Endocrinol (Copenh), 1986;113:88–92.
26. Guo W, Pirtskhalava T, Tchkonia T, et al., Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity, Am J Physiol Endocrinol Metab, 2007;292:E1041–51.
27. Krabbe KS, Pedersen M, Bruunsgaard H, Inflammatory mediators in the elderly, Exp Gerontol, 2004;39:687–99.
28. Chung S, Lapoint K, Martinez K, et al., Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes, Endocrinology, 2006;147:5340–51.
29. Harkins JM, Moustaid-Moussa N, Chung YJ, et al., Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice, J Nutr, 2004;134:2673–7.
30. Lumeng CN, Liu J, Geletka L, et al., Aging Is Associated with an Increase in T Cells and Inflammatory Macrophages in Visceral Adipose Tissue, J Immunol, 2011;187:6208–16.
31. Shimizu H, Ross RK, Bernstein L, et al., Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County, Br J Cancer, 1991;63:963–6.
32. Lee J, Demissie K, Lu SE, Rhoads GG, Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea, Cancer Control, 2007;14:78–85.
33. Parkin DM, Whelan SL, Ferlay J, et al. (eds), Cancer Incidence in Five Continents, Vol. VII, Lyon: IARC Scientific
Publications No 143, 1997.
34. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 2003;348:1625–38.
35. Shimizu H, Ross RK, Bernstein L, Possible underestimation of the incidence rate of prostate cancer in Japan, Jpn J Cancer Res, 1991;82:483–5.
36. Shibata A, Whittemore AS, Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk, Prostate, 1997;32:65–72.
37. Popkin BM, The nutrition transition in low-income countries: an emerging crisis, Nutr Rev, 1994;52:285–98.
38. Hsing AW, Devesa SS, Jin F, Gao YT, Rising incidence of prostate cancer in Shanghai, China, Cancer Epidemiol Biomarkers Prev, 1998;7:83–4.
39. Nomura AM, Kolonel LN, Prostate cancer: a current perspective, Epidemiol Rev, 1991;13:200–27.
40. Villers A, Soulié M, Haillot O, Boccon-Gibod L, [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers], Prog Urol, 1997;7:655–61.
41. Breslow N, Chan CW, Dhom G, et al., Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France, Int J Cancer, 1977;20:680–8.
42. Rodriguez C, Freedland SJ, Deka A, et al., Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort, Cancer Epidemiol Biomarkers Prev, 2007;16:63–9.
43. Gong Z, Neuhouser ML, Goodman PJ, et al., Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial, Cancer Epidemiol Biomarkers Prev, 2006;15:1977–83.
44. Engeland A, Tretli S, Bjorge T, Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men, Br J Cancer, 2003;89:1237–42.
45. Rodriguez C, Patel AV, Calle EE, et al., Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States, Cancer Epidemiol Biomarkers Prev, 2001;10:345–53.
46. Freedland SJ, Wen J, Wuerstle M, et al., Obesity is a significant risk factor for prostate cancer at the time of biopsy, Urology, 2008;72:1102–5.
47. Platz EA, Leitzmann MF, Rifai N, et al., Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era, Cancer Epidemiol Biomarkers Prev, 2005;14:1262–9.
48. Gapstur SM, Kopp P, Gann PH, et al., Changes in BMI modulate age-associated changes in sex hormone binding globulin and total testosterone, but not bioavailable testosterone in young adult men: the CARDIA Male Hormone Study, Int J Obes (Lond), 2007;31:685–91.
49. Orwoll E, Nielson CM, Marshall LM, et al., Vitamin D deficiency in older men, J Clin Endocrinol Metab, 2009;94:1214–22.
50. Kuchuk NO, Pluijm SM, van Schoor NM, et al., Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons, J Clin Endocrinol Metab, 2009;94:1244–50.
51. Mason RS, Sequeira VB, Gordon-Thomson C, Vitamin D: the light side of sunshine, Eur J Clin Nutr, 2011;65:986–93.
52. Deeb KK, Trump DL, Johnson CS, Vitamin D signalling pathways in cancer: potential for anticancer therapeutics, Nat Rev Cancer, 2007;7:684–700.
53. Barnett CM, Nielson CM, Shannon J, et al., Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men, Cancer Causes Control, 2010;21:1297–303.
54. Proctor MJ, Morrison DS, Talwar D, et al., An inflammation- based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study, Br J Cancer, 2011;104:726–34.
55. McArdle PA, Qayyum T, McMillan DC, Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up, Urol Int, 2010;84:430–5.
56. Adler HL, McCurdy MA, Kattan MW, et al., Elevated levels of circulating interleukin-6 and transforming growth factor- beta1 in patients with metastatic prostatic carcinoma, J Urol, 1999;161:182–7.
57. Angelucci A, Garofalo S, Speca S, et al., Arachidonic acid modulates the crosstalk between prostate carcinoma and
bone stromal cells, Endocr Relat Cancer, 2008;15:91–100.
58. Bruunsgaard H, The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality, Dan Med Bull, 2006;53:285–309.
59. Wisse BE, The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity, J Am Soc Nephrol, 2004;15:2792–800.
60. Nakashima J, Tachibana M, Horiguchi Y, et al., Serum interleukin 6 as a prognostic factor in patients with prostate cancer, Clin Cancer Res, 2000;6:2702–6.
61. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB, The role of inflammation in the pathogenesis of prostate cancer, J Urol, 2004;172(5 Pt 2):S6–11; discussion S11–2.
62. Kaaks R, Lukanova A, Sommersberg B, Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review, Prostate Cancer Prostatic Dis, 2000;3:157–72.
63. Tande AJ, Platz EA, Folsom AR, The metabolic syndrome is associated with reduced risk of prostate cancer, Am J Epidemiol, 2006;164:1094–102.
64. Lund Håheim L, Wisløff TF, Holme I, Nafstad P, Metabolic syndrome predicts prostate cancer in a cohort of middle- aged Norwegian men followed for 27 years, Am J Epidemiol, 2006;164:769–74.
65. Schwartz MW, Woods SC, Porte D Jr, et al., Central nervous system control of food intake, Nature, 2000;404:661–71.
66. Judge MK, Zhang J, Tümer N, et al., Prolonged hyperphagia with high-fat feeding contributes to exacerbated weight gain in rats with adult-onset obesity, Am J Physiol Regul Integr Comp Physiol, 2008;295:R773–80.
67. Legradi G, Emerson CH, Ahima RS, et al., Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus, Endocrinology, 1997;138:2569–76.
68. Ahima RS, Prabakaran D, Mantzoros C, et al., Role of leptin in the neuroendocrine response to fasting, Nature, 1996;382:250–2.
69. Nazian SJ, Cameron DF, Temporal relation between leptin and various indices of sexual maturation in the male rat, J Androl, 1999;20:487–91.
70. Zhang Y, Proenca R, Maffei M, et al., Positional cloning of the mouse obese gene and its human homologue, Nature, 1994;372:425–32.
71. Hoon Kim J, Lee SY, Myung SC, et al., Clinical significance of the leptin and leptin receptor expressions in prostate tissues, Asian J Androl, 2008;10:923–8.
72. Saglam K, Aydur E, Yilmaz M, Göktaş S, Leptin influences cellular differentiation and progression in prostate cancer,
J Urol, 2003;169:1308–11.
73. Chang S, Hursting SD, Contois JH, et al., Leptin and prostate cancer, Prostate, 2001;46:62–7.
74. Ribeiro R, Vasconcelos A, Costa S, et al., Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease, Prostate, 2004;59:268–74.
75. Somasundar P, Frankenberry KA, Skinner H, et al., Prostate cancer cell proliferation is influenced by leptin, J Surg Res, 2004;118:71–82.
76. Onuma M, Bub JD, Rummel TL, Iwamoto Y, Prostate cancer cell-adipocyte interaction: leptin mediates androgen- independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase, J Biol Chem, 2003;278:42660–7.
77. Ouchi N, Kihara S, Funahashi T, et al., Obesity, adiponectin and vascular inflammatory disease, Curr Opin Lipidol, 2003;14:561–6.
78. Xu A, Wang Y, Keshaw H, et al., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J Clin Invest, 2003;112:91–100.
79. Ohashi K, Parker JL, Ouchi N, et al., Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype, J Biol Chem, 2010;285:6153–60.
80. Mistry T, Digby JE, Chen J, et al., The regulation of adiponectin receptors in human prostate cancer cell lines, Biochem Biophys Res Commun, 2006;348:832–8.
81. Michalakis K, Williams CJ, Mitsiades N, et al., Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study, Cancer Epidemiol Biomarkers Prev, 2007;16:308–13.
82. Sher DJ, Oh WK, Jacobus S, et al., Relationship between serum adiponectin and prostate cancer grade, Prostate, 2008;68:1592–8.
EUROPEAN ONCOLOGY & HAEMATOLOGY
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77